This also suggests that combining biomarkers of GOF mutant p53 in the cancer cell compartment with high HSPG2 stromal deposition may be used in the future to identify patients that could benefit from HSPG2 manipulation in combination with chemotherapy. This evidence concerns the gene TP53 and cancer.